Retatrutide Dosage Chart: Reconstitution, Titration & FAQ | FormBlends

Trust Signals

This page is authored by the FormBlends Medical Team. All trial statistics are sourced to named, peer-reviewed publications. Every claim is evidence-graded. Retatrutide is an investigational compound; no claim here constitutes medical advice. Consult a licensed clinician before any use.

Key Takeaways

• The Jastreboff et al. 2023 Phase 2 trial (NEJM) established the titration ramp: starting at 0.5 mg once weekly, escalating to a maximum of 4 mg, 8 mg, or 12 mg depending on arm assignment over 24 weeks.
• A 10 mg vial reconstituted with 2 mL BAC water yields 5 mg/mL; at a 0.5 mg starting dose that vial covers 20 weekly injections.
• Retatrutide's reported human half-life of approximately 6 days supports once-weekly dosing and makes missed-dose timing clinically meaningful.
• The 12 mg dose group achieved a mean body weight reduction of approximately 24.2% at 48 weeks (n=72); nausea affected the majority of higher-dose participants during the ramp phase.
• Retatrutide is not FDA approved as of May 2026; Phase 3 trials are ongoing and no approved dosing standard exists outside of investigational protocols.

What Is the Retatrutide Dosage and How Does It Work?

Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors in a single molecule. The starting dose in clinical trials is 0.5 mg subcutaneous once weekly, escalated stepwise over months to maintenance doses of 4 mg, 8 mg, or 12 mg. No FDA-approved dosing standard exists. The information below reflects the published Phase 2 protocol.

Table of Contents

• Evidence Ledger: What the Data Actually Shows
• Retatrutide Dosage Chart: Phase 2 Titration Schedule
• How Long Will 10 mg of Retatrutide Last?
• Reconstitution Math: 10 mg, 20 mg, and 30 mg Vials
• How Much BAC Water for 10 mg Retatrutide?
• Mechanism with Numbers: Why Triple Agonism Changes the Dose Ceiling
• What Most Pages Get Wrong About Retatrutide Dosing
• Stability and Storage: The Chemistry Behind the Rules
• Honest Head-to-Head: Retatrutide vs. Semaglutide vs. Tirzepatide
• Operational Label Literacy: Reading a COA and Spotting Degradation
• FAQ
• Sources

Evidence Ledger: What the Data Actually Shows

Retatrutide Dosage Chart: Phase 2 Titration Schedule

The titration below mirrors the protocol used in Jastreboff et al. 2023. The actual escalation step depends on which maximum-dose arm a participant was assigned to. All three arms shared the same early ramp; divergence occurred at week 17.

How Long Will 10 mg of Retatrutide Last?

This depends entirely on your current weekly dose. The table below shows vial duration at common dose levels.

Practical takeaway: at maintenance doses of 8-12 mg per week, a single 10 mg vial does not last one full week. Researchers at higher dose tiers typically work with 20 mg or 30 mg vials to reduce reconstitution frequency and concentration-related measurement error.

Reconstitution Math: 10 mg, 20 mg, and 30 mg Vials

How Much BAC Water for 10 mg Retatrutide?

The most practical choice for a 10 mg vial is 2 mL of bacteriostatic water, yielding 5 mg/mL. This concentration keeps doses measurable on a standard insulin syringe throughout the titration ramp (0.5 mg = 10 units, 2 mg = 40 units, 4 mg = 80 units) without requiring sub-5-unit measurements that introduce meaningful volume error.

Using only 1 mL (10 mg/mL) is mathematically valid at higher doses but makes the 0.5 mg starting dose equal to 5 units, where a one-unit error represents a 20% dose variance. Worse for titration-phase accuracy.

Reconstitution technique: Draw the BAC water into a syringe. Insert the needle at an angle into the vial stopper. Allow the BAC water to run slowly down the interior vial wall rather than jetting directly onto the lyophilized cake. Swirl gently; do not shake or vortex. Shaking introduces air-water interface shear stress that can cause peptide aggregation.

Mechanism with Numbers: Why Triple Agonism Changes the Dose Ceiling

Retatrutide (LY3437943) is a fatty-acid-modified peptide that activates three receptors simultaneously:

• GLP-1R (glucagon-like peptide-1 receptor): Slows gastric emptying, stimulates insulin secretion, suppresses appetite centrally via hypothalamic and brainstem pathways.
• GIPR (glucose-dependent insulinotropic polypeptide receptor): Augments insulin secretion in a glucose-dependent manner; may attenuate GLP-1-driven nausea, which is one reason dual/triple agonists tolerate higher effective doses than GLP-1 mono-agonists.
• GCGR (glucagon receptor): Increases hepatic glucose output in isolation, but in the context of GLP-1/GIP co-agonism, the net effect is increased energy expenditure and enhanced fat oxidation rather than hyperglycemia.

The fatty acid modification (C20 diacid moiety) enables albumin binding, extending the plasma half-life to approximately 6 days in humans -- comparable to semaglutide's 7-day half-life -- and supporting once-weekly injection. This structural feature is why the molecule cannot simply be dissolved in saline for stability; the fatty acid tail creates surface-active properties that are sensitive to agitation and temperature.

What Most Pages Get Wrong About Retatrutide Dosing

This is the section competitors skip.

1. Vial purity is not guaranteed by vendor claims. Retatrutide is a complex fatty-acid-conjugated peptide. HPLC purity testing can detect small-molecule impurities but may miss aggregated or misfolded peptide species that retain some chromatographic identity. A COA showing "99% purity" by HPLC does not confirm biological potency or the absence of immunogenic aggregates. Request mass spectrometry confirmation of the correct molecular weight (the monoisotopic mass for retatrutide is approximately 4,859 Da) alongside HPLC data.

2. The 24.2% weight loss figure is a mean, not a floor. In the 12 mg arm of Jastreboff et al. 2023, there was meaningful individual variance. Some participants lost substantially less; a subset lost more. Presenting the mean as a predictable outcome misrepresents the trial data.

3. No dose-response data exists above 12 mg in humans. Community discussion of "higher maintenance doses" has no clinical evidence base. The 12 mg ceiling in Phase 2 was a protocol decision; there is no published safety or efficacy data for doses exceeding 12 mg per week in humans.

4. Reconstituted vial stability is not indefinitely extended by refrigeration. Peptide degradation continues in solution even at 2-8 degrees C; it is slowed, not stopped. Most lyophilized research peptides are used within 28-30 days of reconstitution when stored refrigerated. There is no published stability-kinetics study for reconstituted retatrutide from research-grade sources. Treat 30 days as a conservative upper limit.

Stability and Storage: The Chemistry Behind the Rules

Retatrutide is supplied as a lyophilized (freeze-dried) powder. Lyophilization removes water to arrest hydrolytic degradation, which is the primary degradation pathway for peptide bonds: water molecules attack amide bonds in the peptide backbone.

Why cold storage matters: Arrhenius kinetics governs reaction rates. A temperature increase of roughly 10 degrees C approximately doubles the rate of most chemical reactions. Storing reconstituted retatrutide at room temperature (22 degrees C) rather than refrigerated (4 degrees C) roughly quadruples the degradation rate. This is not specific to retatrutide; it is a universal peptide chemistry principle.

Why freeze-thaw cycling is harmful: Ice crystal formation during freezing physically disrupts peptide secondary structure and can cause irreversible aggregation. The fatty acid tail on retatrutide is particularly susceptible because it participates in non-covalent self-assembly that is disrupted by ice-mediated mechanical stress. Once reconstituted, do not freeze the solution.

Why BAC water outperforms sterile water: Bacteriostatic water contains 0.9% benzyl alcohol, a bacteriostatic preservative. This extends usable vial life to approximately 28-30 days by preventing microbial contamination of a multi-use vial. Sterile water is preservative-free and appropriate only for single-use reconstitution.

Light sensitivity: Peptide photo-oxidation (particularly at tryptophan, methionine, and histidine residues) occurs under UV exposure. Store vials in the original box or a dark container. This is why pharmaceutical GLP-1 pens are opaque.

Honest Head-to-Head: Retatrutide vs. Semaglutide vs. Tirzepatide

Bottom line: Retatrutide shows greater weight loss in early data, but semaglutide and tirzepatide have one thing retatrutide lacks entirely: proven cardiovascular safety, regulatory oversight, and a controlled supply chain. For a clinically supervised patient, an approved agent is the lower-risk choice today.

Operational Label Literacy: Reading a COA and Spotting Degradation

What a legitimate COA should contain for retatrutide:

• Sequence confirmation or molecular weight by mass spectrometry (expected: approximately 4,859 Da monoisotopic; confirm with vendor's stated value against published literature)
• HPLC purity, with the column and method described (a number without a method is unverifiable)
• Endotoxin testing result (LAL assay; should be below 1 EU/mg for injectable research use)
• Sterility or bioburden data if the product is supplied as a solution rather than lyophilized
• Lot number traceable to the document

Signs of a degraded or compromised reconstituted vial:

• Visible particulates or cloudiness in what should be a clear solution
• Distinct yellow-brown discoloration (slight yellow is acceptable; amber is not)
• Precipitate that does not redissolve after gentle swirling at room temperature
• Unexplained reduction in expected biological effect over the course of a vial (a qualitative but useful signal)

Syringe selection: Use a 29-31 gauge, 0.5 inch needle for subcutaneous injection. A 1 mL U-100 insulin syringe with a fixed needle minimizes dead-space volume loss, which matters when measuring 0.1-0.2 mL doses.

FAQ

What is the starting dose for retatrutide?
In the Eli Lilly Phase 2 trial (NCT04881760), participants started at 0.5 mg subcutaneous once weekly for four weeks before the first dose escalation. This low starting dose was chosen to minimize GI side effects as GLP-1 receptor agonism can cause nausea at higher doses without a ramp.

How long will 10 mg of retatrutide last?
At 0.5 mg per week (the starting dose), a 10 mg vial covers 20 weeks. At 4 mg per week (a mid-tier maintenance dose used in the Phase 2 trial), the same vial lasts approximately 2.5 weeks. Your actual duration depends entirely on the weekly dose you are using.

How much BAC water do I add to a 10 mg retatrutide vial?
Adding 2 mL of bacteriostatic water to a 10 mg vial gives a concentration of 5 mg/mL (5,000 mcg/mL). Adding 1 mL gives 10 mg/mL. Most researchers use 2 mL because it yields easier-to-measure volumes on an insulin syringe at low doses. Always inject BAC water slowly along the vial wall to avoid denaturing the peptide.

How do I reconstitute a 30 mg retatrutide vial?
Adding 3 mL of BAC water to a 30 mg vial gives 10 mg/mL. Adding 6 mL gives 5 mg/mL, which is easier to dose at sub-milligram amounts. At 5 mg/mL, a 0.5 mg dose equals 10 units on a U-100 insulin syringe. Choose the dilution that keeps your injection volume between 0.1 and 0.5 mL.

What doses were used in the retatrutide Phase 2 trial?
The 48-week Phase 2 trial (Jastreboff et al., NEJM 2023) tested three dose groups: 4 mg, 8 mg, and 12 mg maximum doses with a standardized titration ramp starting at 0.5 mg once weekly. The 12 mg group achieved a mean body weight reduction of approximately 24.2% at 48 weeks (n=72 in that arm).

What is the half-life of retatrutide and how does it affect dosing frequency?
Retatrutide has a reported half-life of approximately 6 days in humans, which supports once-weekly subcutaneous dosing. At steady state with once-weekly injections, plasma levels remain relatively stable across the dosing interval with limited peak-to-trough fluctuation.

What injection sites are used for retatrutide?
Subcutaneous injection into the abdomen (at least 2 inches from the navel), upper thigh, or upper arm is standard, consistent with other GLP-1/GIP-based peptides. Rotating sites each week reduces localized lipoatrophy risk.

How do I know if my reconstituted retatrutide has degraded?
A properly reconstituted solution should be clear and colorless to very slightly yellow. Visible particulates, cloudiness, or a distinctly yellow-brown color are signs of degradation or contamination and the vial should be discarded. Degradation accelerates above 8 degrees C and with repeated freeze-thaw cycles.

How does retatrutide compare to semaglutide for weight loss?
In their respective Phase 2/3 trials, semaglutide 2.4 mg (Wegovy) achieved approximately 14.9% body weight reduction at 68 weeks (STEP 1 trial, Wilding et al. NEJM 2021), while retatrutide 12 mg achieved approximately 24.2% at 48 weeks (Jastreboff et al. NEJM 2023). These are different trial designs and populations, so a direct comparison is not statistically valid, but the directional signal favors retatrutide.

Is retatrutide FDA approved?
No. As of May 2026, retatrutide (LY3437943) is an investigational compound in Phase 3 clinical trials. It is not FDA approved for any indication. It is not legally available as a prescription drug in the United States and should be understood as a research compound only.

What concentration should I use for a 20 mg retatrutide vial?
Adding 2 mL of BAC water to a 20 mg vial yields 10 mg/mL. Adding 4 mL yields 5 mg/mL. At 5 mg/mL, a 0.5 mg dose = 10 units on a U-100 syringe, and a 4 mg dose = 80 units. Most researchers prefer the 5 mg/mL dilution for titration-phase dosing because of its easier measurement at low volumes.

What are the most common side effects of retatrutide?
In the Jastreboff et al. 2023 Phase 2 trial, the most frequently reported adverse events were GI-related: nausea (reported in roughly 40-60% of higher-dose participants), vomiting, diarrhea, and constipation. Most events were mild to moderate and occurred during dose escalation. Injection site reactions were uncommon.

Sources

1. Jastreboff AM, Kaplan LM, Frías JP, et al.

   Related peptide guides

   • Peptide therapy guide hub
   • Peptide dosage and reconstitution calculator
   • Cagrilintide Dosage With Tirzepatide: Full Reconstitution & Dosing Chart | FormBlends
   • How Much Bac Water to Reconstitute Peptides: Dosage Guide | FormBlends
   • GHRP-2 Dosage: Evidence-Based Guide | FormBlends
   • Glow Peptide Dosage: Protocol, Chart & Dosing Guide | FormBlends
   • How to Take Reta Peptide: Dosing, Injection, and Protocol Guide | FormBlends